BHC (Bausch Health Companies Inc.) Aggregate Asset Value

BHC (Bausch Health Companies Inc.) - company brandmark

Bausch Health Companies (BHC) is developing an ecosystem in dermatology and gastroenterology, creating barriers to therapy switching. Revenues are based on ophthalmology and pharmaceutical sales. The holding company is currently restructuring its business to reduce its debt load. This total assets chart reflects resource dynamics, where the metric level stands at 26118.01, helping investors assess the company's book value without market emotion.

bauschhealth.com (BHC) Aggregate Company Assets: for the period 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for Valeant Pharmaceuticals (BHC)

- current price and projected stock value:
Quote Chart bauschhealth.com|BHC - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Bausch Health Corp|BHC - Enterprise Value
- business book valuation details:
Book Value per Share Bausch Health|BHC - Company Book Value|Market Value to Book Value bauschhealth.com|BHC - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Bausch Health Companies|BHC - Long-Term Debt to Capital|Short-Term Debt to Capital Bausch Health Corp|BHC - Company Total Debt|Debt to Net Assets Ratio Bausch Health Corp|BHC - Company Long-Term Debts|Company Short-Term Loans and Borrowings Bausch Health|Immediate Liquidity bauschhealth.com
- earnings and market multiples details:
BHC - Company Net Income
Summary company analysis:bauschhealth.com (BHC)
Core merchandise of Valeant Pharmaceuticals

To select high-quality assets, an investor must weigh the actual scale of the business against its debt load to avoid overpaying for the security. This indicator inversely calculates the aggregate of resources and capital via return on assets (ROA), reflecting the material base of Bausch Health Companies (BHC) in ophthalmology and cosmetology, which allows for an assessment of the diversified portfolio's stability through the growth of assets and resources.

Direct competitors

Total Asset Value of Company LLY (lilly.com)|ABBV (AbbVie) - Company Total Assets|AZN: Aggregate Asset Value|Company Total Assets NVS|Company Total Assets MSD (MRK)|Aggregate Company Assets Novo Nordisk A/S NVO|Aggregate Asset Value AMGN|PFE - Aggregate Company Assets|Sanofi SA (SNY) - Cumulative Company Assets|BMY: Company Total Assets|GlaxoSmithKline (GSK) - Company Total Assets|Cumulative Company Assets TAK|TEVA: Aggregate Asset Value|Company Total Assets RDY|VTRS (Viatris Inc) - Aggregate Asset Value|Aggregate Company Assets Roivant Sciences Ltd ROIV|Zai Lab Corp (ZLAB) - Company Assets|COSM - Aggregate Company Assets